MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
24h
Current
Min
14.93
Max
15.8
Income | 28M 8.2M |
|---|---|
Sales | 351K 351K |
P/E Sector Avg | 18.136 89.037 |
EPS | 0.94 |
Profit margin | 2,337.322 |
Employees | 103 |
EBITDA | 28M 9.3M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +40.75% upside |
Next Earnings | 12 mar 2026 |
|---|
Market Cap | 11M 144M |
|---|---|
Previous open | 16.77 |
Previous close | 15.15 |
By Acuity
26%
74%
51 / 352 Ranking in Healthcare
By Trading Central
Confidence
Bearish Evidence
N/A / 9.31 Support & Resistance
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 sty 2026, 23:07 UTC
Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update
DJ
Read
27 sty 2026, 21:27 UTC
Texas Instruments 4Q Sales Rise, Profit Falls
DJ
Read
27 sty 2026, 23:55 UTC
Yen Weakens Slightly on Possible Technical Correction -- Market Talk
DJ
Read
27 sty 2026, 23:47 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
Read
27 sty 2026, 23:47 UTC
Nikkei May Decline Amid Caution Over Earnings -- Market Talk
DJ
Read
27 sty 2026, 23:39 UTC
Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk
DJ
Read
27 sty 2026, 23:20 UTC
SK Innovation: Asset-Impairment Losses Weighed on Earnings
DJ
Read
27 sty 2026, 23:20 UTC
SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings
DJ
Read
27 sty 2026, 23:19 UTC
SK Innovation Posts Net Loss for Second Consecutive Year
DJ
Read
27 sty 2026, 23:19 UTC
SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE
DJ
Read
27 sty 2026, 23:18 UTC
SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE
DJ
Read
27 sty 2026, 23:18 UTC
SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE
DJ
Read
27 sty 2026, 23:11 UTC
Global Equities Roundup: Market Talk
DJ
Read
27 sty 2026, 23:11 UTC
Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk
DJ
Read
27 sty 2026, 23:07 UTC
Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk
DJ
Read
27 sty 2026, 22:17 UTC
U.S. Dollar Slips Following Trump Comments -- Market Talk
DJ
Read
27 sty 2026, 22:06 UTC
Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update
DJ
Read
27 sty 2026, 21:51 UTC
Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com
DJ
Read
27 sty 2026, 21:50 UTC
Basic Materials Roundup: Market Talk
DJ
Read
27 sty 2026, 21:43 UTC
RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com
DJ
Read
27 sty 2026, 21:41 UTC
GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update
DJ
Read
27 sty 2026, 21:38 UTC
These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com
DJ
Read
27 sty 2026, 21:32 UTC
Ampol: Modest Profit From F&I International in 2025
DJ
Read
27 sty 2026, 21:32 UTC
Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025
DJ
Read
27 sty 2026, 21:31 UTC
Ampol: New Zealand Ebit in 2025 In Line With Prior Year
DJ
Read
27 sty 2026, 21:31 UTC
Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025
DJ
Read
27 sty 2026, 21:30 UTC
Ampol 4Q Lytton Refinery Production 1.56 Billion Liters
DJ
Read
27 sty 2026, 21:29 UTC
Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion
DJ
Read
27 sty 2026, 21:29 UTC
Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million
DJ
Read
27 sty 2026, 21:28 UTC
Ampol 4Q Lytton Refiner Margin US$15.14/Bbl
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 22 USD 40.75%
High 22 USD
Low 22 USD
Based on 2 Wall Street analysts offering 12 month price targets forSeres Therapeutics Inc - Dist in the last 3 months.
By TipRanks
Buy
2 ratings
2
Buy
0
Hold
0
Sell
Based on 2 analysts giving stock ratings to Seres Therapeutics Inc - Dist in the past 3 months.
By Trading Central
Short Term
Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Bearish Evidence
All events are bearish.
Long Term
Bearish Evidence
All events are bearish.
By Acuity
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$